Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma

BACKGROUND: Metastatic Merkel cell carcinoma (mMCC) is a rare and aggressive skin cancer. Until recently, there were no licensed treatment options for patients with mMCC, and prognosis was poor. A cost-effectiveness analysis was conducted for avelumab, a newly available treatment option for mMCC, ve...

Descripción completa

Detalles Bibliográficos
Autores principales: Bullement, Ash, Nathan, Paul, Willis, Anna, Amin, Amerah, Lilley, Cameron, Stapelkamp, Ceilidh, Hatswell, Anthony, Pescott, Chris, Bharmal, Murtuza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710317/
https://www.ncbi.nlm.nih.gov/pubmed/30680676
http://dx.doi.org/10.1007/s41669-018-0115-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710317/
https://www.ncbi.nlm.nih.gov/pubmed/30680676
http://dx.doi.org/10.1007/s41669-018-0115-y

Ejemplares similares